News

Global Health EDCTP Prizes 2025: applications are now open

Published on
| 1 year ago
Programmes
  • Health

The EDCTP Prizes are open for submissions from 11 March until 1 April 2025 via the Funding and Tenders Portal. Deadline to apply is on 1 April, 17:00 CET.

The EDCTP Prizes will recognise outstanding individuals and research teams from Africa and Europe who have made significant achievements in their research field. Additionally, the awardees will have made major contributions to strengthening clinical research capacity in Africa and supporting South-South and North-South networking. The Prizes will be awarded during the Twelfth EDCTP Forum, taking place on 15-20 June 2025 in Kigali, Rwanda.

Contrary to previous editions, applications for the EDCTP Prizes 2025 are to be submitted by the individuals or teams applying for the Prizes, with supporting letter(s) of recommendation from at least one reputable scientist.

Find out more on the dedicated EDCTP3 webpage and read the Rules of Contest.


The Global Health EDCTP3 Joint Undertaking (GH EDCTP3 JU) is a partnership between the European Union and the European and Developing Countries Clinical Trials Partnership (EDCTP) Association whose members are several EU Member States and Associated countries and several African countries.

Related news

myOverview

Sign up for personalised information

Stay informed about Horizon Europe, Digital Europe & EDF, filtered on what matters to you.

  • News in your domains
  • Event announcements
  • A personal dashboard
Sign up now

Only for stakeholders located in Flanders

Latest news

2055 articles available Browse all news
  • Health

One Health AMR Partnership: Call 2027 opening soon

The European Partnership on One Health Antimicrobial Resistance (OH AMR) is about to launch the joint transnational call 2027 (JTC2027) “Understand, Model and Stop AMR Transmission”. The call opens on 18 November 2026. The call will follow a two-step evaluation process.Novel and improved measures are urgently required...

Read more
  • Enhancing EU R&I

ERA in Practice: A guide for the research and innovation community

The European Commission Directorate-General Research & Innovation has published ERA in Practice: A Guide for the R&I Community, developed with the support of INSPIRING ERA. The publication connects the four European Research Area policy priorities for joint action of the Pact for Research and Innovation (2021), with practical tools and...

Read more
  • Culture and society

SSH Opportunities document for the 2027 Horizon Europe calls updated

Net4Society, the NCP network for Cluster 2, has published an updated edition of the document "Opportunities for Researchers from the Social Sciences and Humanities (SSH) in Horizon Europe". This document is designed to help potential applicants to find SSH-related call topics across the different parts of Horizon Europe in Work Programmes...

Read more
  • Agro-Food, Environment

Topic update - HORIZON-CL6-2027-02-FARM2FORK-05

On 5 November 2026, the European Commission published a correction for Horizon Europe topic HORIZON-CL6-2027-02-FARM2FORK-05. Under the section ‘Topic description - Scope’, the sentence on collaboration with projects funded under other topics in the work programme has been updated. The original text referred to...

Read more

Testimonial

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.